NCT06809140 2026-02-23
Enfortumab Vedotin Plus Pembrolizumab With Selective Bladder Sparing for Treatment of Muscle-invasive Bladder Cancer
Hoosier Cancer Research Network
Phase 2 Recruiting
Clinical Trials
3 trialsNCT06257017 2025-04-04
Surveillance of the Genetic Signature in Circulating Tumor DNA for Guiding Adjuvant Chemotherapy in Urothelial Carcinoma
The University of Hong Kong
Phase 2 Recruiting
NCT06204614 2024-01-12
Drug Screening Using IMD in Bladder Cancer
Brigham and Women's Hospital
Phase EARLY_PHASE1 Unknown